🩻 HIGH-DOSE IVERMECTIN FOR CANCER IS BEING DISCUSSED, BUT THE DOSING QUESTION IS STILL UNRESOLVED
Some clinicians promoting drug repurposing are discussing ivermectin doses around 1 mg/kg for cancer, far above many of the doses historically used for approved antiparasitic indications.
The scientific interest comes from preclinical research.
#Ivermectin has shown activity involving apoptosis, cancer stem cells, angiogenesis, treatment resistance and several tumor-signaling pathways.
#Mebendazole and fenbendazole have also attracted attention through effects on microtubules, glucose metabolism and, in some models, p53-related pathways.
But this is where the evidence gap becomes critical.
There is currently no established
#Oncology guideline showing that 1 mg/kg ivermectin is a validated cancer dose. Higher experimental dosing requires human pharmacokinetic, toxicity and efficacy data before it can be treated as a standard cancer protocol.
The same caution applies to claims that mebendazole or fenbendazole should be used specifically to reverse p53 changes after COVID vaccination. Laboratory hypotheses involving spike protein and p53 have not established that vaccination causes clinically meaningful p53 suppression requiring these drugs.
Off-patent medicines can deserve public funding, especially when commercial incentives are weak. But a lack of patent protection does not prove that an effective cancer therapy is being ignored.
The key questions remain dose, cancer type, combinations, safety and survival benefit in future
#ClinicalTrials.
The scientific community continues to explore how
#DrugRepurposing can safely expand future treatment options.
🔍 Follow
@DrCharlete_ for repurposed medicines, cancer pharmacology and emerging
#CancerResearch evidence.
#Ivermectin #Mebendazole #Fenbendazole #CancerResearch #DrugRepurposing #Oncology #ClinicalTrials